Last week, the Food and Drug Administration (FDA) announced that it has published a list of licensed biological products and interchangeable biosimilars to be known as the Purple Book. The Purple Book is meant to be the biological equivalent of the pharmaceutical “Orange Book,” which is used by government agencies and healthcare providers to identify … Continue Reading